313 related articles for article (PubMed ID: 19193873)
1. Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model.
Tang TS; Guo C; Wang H; Chen X; Bezprozvanny I
J Neurosci; 2009 Feb; 29(5):1257-66. PubMed ID: 19193873
[TBL] [Abstract][Full Text] [Related]
2. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
3. Inositol 1,4,5-tripshosphate receptor, calcium signalling and Huntington's disease.
Bezprozvanny I
Subcell Biochem; 2007; 45():323-35. PubMed ID: 18193642
[TBL] [Abstract][Full Text] [Related]
4. Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.
Bezprozvanny I
Neurochem Res; 2011 Jul; 36(7):1186-97. PubMed ID: 21210219
[TBL] [Abstract][Full Text] [Related]
5. Dantrolene is neuroprotective in Huntington's disease transgenic mouse model.
Chen X; Wu J; Lvovskaya S; Herndon E; Supnet C; Bezprozvanny I
Mol Neurodegener; 2011 Nov; 6():81. PubMed ID: 22118545
[TBL] [Abstract][Full Text] [Related]
6. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
7. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
8. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1.
Tang TS; Tu H; Chan EY; Maximov A; Wang Z; Wellington CL; Hayden MR; Bezprozvanny I
Neuron; 2003 Jul; 39(2):227-39. PubMed ID: 12873381
[TBL] [Abstract][Full Text] [Related]
9. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
10. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
11. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
12. Expanded huntingtin activates the c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neurons in culture.
Garcia M; Charvin D; Caboche J
Neuroscience; 2004; 127(4):859-70. PubMed ID: 15312898
[TBL] [Abstract][Full Text] [Related]
13. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
14. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
15. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
16. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease.
Tang TS; Slow E; Lupu V; Stavrovskaya IG; Sugimori M; Llinás R; Kristal BS; Hayden MR; Bezprozvanny I
Proc Natl Acad Sci U S A; 2005 Feb; 102(7):2602-7. PubMed ID: 15695335
[TBL] [Abstract][Full Text] [Related]
17. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
18. Deranged neuronal calcium signaling and Huntington disease.
Bezprozvanny I; Hayden MR
Biochem Biophys Res Commun; 2004 Oct; 322(4):1310-7. PubMed ID: 15336977
[TBL] [Abstract][Full Text] [Related]
19. CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.
Apostol BL; Simmons DA; Zuccato C; Illes K; Pallos J; Casale M; Conforti P; Ramos C; Roarke M; Kathuria S; Cattaneo E; Marsh JL; Thompson LM
Mol Cell Neurosci; 2008 Sep; 39(1):8-20. PubMed ID: 18602275
[TBL] [Abstract][Full Text] [Related]
20. In vivo cell-autonomous transcriptional abnormalities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons.
Thomas EA; Coppola G; Tang B; Kuhn A; Kim S; Geschwind DH; Brown TB; Luthi-Carter R; Ehrlich ME
Hum Mol Genet; 2011 Mar; 20(6):1049-60. PubMed ID: 21177255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
